RILPL2

Summary

RILPL2 (Rab interacting lysosomal protein like 2, HGNC:28787) is a protein-coding gene on chromosome 12q24.31, encoding RILP-like protein 2 (Q969X0). Involved in cell shape and neuronal morphogenesis, positively regulating the establishment and maintenance of dendritic spines.

This gene encodes a protein that contains a rab-interacting lysosomal protein-like domain. This protein may be involved in regulating lysosome morphology. This protein may also be a target for the Hepatitis C virus and assist in viral replication. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 196383 — RefSeq curated summary.

At a glance

• GWAS associations: 25
• Clinical variants (ClinVar): 40 total
• MANE Select transcript: NM_145058

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28787
Approved symbol	RILPL2
Name	Rab interacting lysosomal protein like 2
Location	12q24.31
Locus type	gene with protein product
Status	Approved
Aliases	MGC7036, FLJ30380, FLJ32372
Ensembl gene	ENSG00000150977
Ensembl biotype	protein_coding
OMIM	614093
Entrez	196383

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 nonsense_mediated_decay

ENST00000280571, ENST00000718482, ENST00000718483, ENST00000718484, ENST00000718485, ENST00000884090, ENST00000884091

RefSeq mRNA: 1 — MANE Select: NM_145058 NM_145058

CCDS: CCDS9248

Canonical transcript exons

ENST00000280571 — 4 exons

Exon	Start	End
ENSE00000996988	123423044	123423157
ENSE00001100430	123415039	123415921
ENSE00001432183	123430508	123430659
ENSE00004035230	123436082	123436684

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 97.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.8441 / max 3220.8405, expressed in 1806 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
133946	19.8767	1707
133947	7.4839	1097
133948	6.0828	1543
133949	1.6371	822
133950	0.7637	515

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	97.60	gold quality
vena cava	UBERON:0004087	95.53	gold quality
pharyngeal mucosa	UBERON:0000355	95.15	gold quality
pancreatic ductal cell	CL:0002079	95.01	gold quality
cauda epididymis	UBERON:0004360	94.95	gold quality
nasal cavity epithelium	UBERON:0005384	94.66	gold quality
body of tongue	UBERON:0011876	94.66	gold quality
saphenous vein	UBERON:0007318	94.64	gold quality
tongue	UBERON:0001723	94.62	gold quality
pons	UBERON:0000988	94.16	gold quality
superior surface of tongue	UBERON:0007371	94.15	gold quality
trabecular bone tissue	UBERON:0002483	94.08	gold quality
kidney epithelium	UBERON:0004819	93.94	silver quality
esophagus squamous epithelium	UBERON:0006920	93.79	gold quality
tibia	UBERON:0000979	93.78	gold quality
trachea	UBERON:0003126	93.73	gold quality
bronchus	UBERON:0002185	93.35	gold quality
bronchial epithelial cell	CL:0002328	93.32	gold quality
lower lobe of lung	UBERON:0008949	93.13	gold quality
pericardium	UBERON:0002407	93.00	gold quality
epithelium of nasopharynx	UBERON:0001951	92.83	gold quality
urethra	UBERON:0000057	92.80	gold quality
myocardium	UBERON:0002349	92.15	silver quality
palpebral conjunctiva	UBERON:0001812	91.83	gold quality
monocyte	CL:0000576	91.57	gold quality
middle temporal gyrus	UBERON:0002771	91.53	gold quality
buccal mucosa cell	CL:0002336	91.46	gold quality
caput epididymis	UBERON:0004358	91.34	gold quality
superficial temporal artery	UBERON:0001614	91.28	gold quality
seminal vesicle	UBERON:0000998	91.18	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	34.96
E-MTAB-9467	yes	17.75
E-ANND-3	yes	15.13
E-GEOD-135922	yes	10.49

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

51 targeting RILPL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6740-3P	99.48	68.49	1392
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-5009-3P	99.45	69.43	1341
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-145-3P	99.33	67.66	764
HSA-MIR-7515	99.31	68.22	1795
HSA-MIR-488-5P	99.28	68.12	821
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-4528	99.18	69.77	1936

Literature-anchored findings (GeneRIF, showing 3)

• Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. (PMID:32017888)
• LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ciliogenesis blockade. (PMID:33727250)
• Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer. (PMID:36536539)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rilpl2	ENSDARG00000024818
mus_musculus	Rilpl2	ENSMUSG00000029401
rattus_norvegicus	Rilpl2	ENSRNOG00000001061
drosophila_melanogaster	Rilpl	FBGN0024985
caenorhabditis_elegans		WBGENE00007860

Paralogs (4): DZIP1 (ENSG00000134874), DZIP1L (ENSG00000158163), RILP (ENSG00000167705), RILPL1 (ENSG00000188026)

Protein

Protein identifiers

RILP-like protein 2 — Q969X0 (reviewed: Q969X0)

Alternative names: Rab-interacting lysosomal protein-like 2, p40phox-binding protein

All UniProt accessions (1): Q969X0

UniProt curated annotations — full annotation on UniProt →

Function. Involved in cell shape and neuronal morphogenesis, positively regulating the establishment and maintenance of dendritic spines. Plays a role in cellular protein transport, including protein transport away from primary cilia. May function via activation of RAC1 and PAK1.

Subunit / interactions. Homodimer. Interacts with RAC1. Interacts (via N-terminus) with MYO5A, the interaction is required for its role in dendrite formation. Interacts with RAB8A; interaction is dependent on the phosphorylation of RAB8A on ‘Thr-72’. Interacts with RAB10 and RAB12; interaction is dependent on the phosphorylation of ‘Thr-73’ on RAB10 and ‘Ser-105’ on RAB12.

Subcellular location. Cytoplasm. Cytosol. Cytoskeleton. Microtubule organizing center. Centrosome. Cell projection. Cilium.

Tissue specificity. Widely expressed. Expressed at higher level in lung.

Similarity. Belongs to the RILPL family.

RefSeq proteins (1): NP_659495* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021563	RILP_dimer	Domain
IPR034743	RH1	Domain
IPR034744	RH2	Domain
IPR051241	DZIP_RILPL	Family

Pfam: PF09744, PF11461

UniProt features (12 total): mutagenesis site 3, domain 2, region of interest 2, chain 1, helix 1, coiled-coil region 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6SQ2	X-RAY DIFFRACTION	1.68
6RIR	X-RAY DIFFRACTION	1.77
7LWB	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969X0-F1	77.73	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 107

Mutagenesis-validated functional residues (3):

Position	Phenotype
149	loss of interaction with rab8a, rab10 and rab12.
130	loss of interaction with rab8a, rab10 and rab12.
132	loss of interaction with rab8a, rab10 and rab12.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 224 (showing top): GOBP_EPITHELIUM_DEVELOPMENT, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_EPITHELIAL_CELL_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOMF_GTPASE_BINDING, CHANDRAN_METASTASIS_DN, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOCC_MICROTUBULE_ORGANIZING_CENTER, MARTINEZ_RB1_TARGETS_DN, KOYAMA_SEMA3B_TARGETS_UP, GOBP_CILIUM_ORGANIZATION, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, GOCC_CENTROSOME, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE

GO Biological Process (4): epithelial cell morphogenesis (GO:0003382), cilium assembly (GO:0060271), protein transport from ciliary membrane to plasma membrane (GO:1903445), protein transport (GO:0015031)

GO Molecular Function (5): small GTPase binding (GO:0031267), identical protein binding (GO:0042802), protein dimerization activity (GO:0046983), dynein light intermediate chain binding (GO:0051959), protein binding (GO:0005515)

GO Cellular Component (8): cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), cilium (GO:0005929), membrane (GO:0016020), ciliary basal body (GO:0036064), cytoskeleton (GO:0005856), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
protein binding	3
microtubule organizing center	2
cell morphogenesis	1
epithelial cell development	1
axoneme assembly	1
intraciliary transport involved in cilium assembly	1
cilium organization	1
protein localization to cilium	1
organelle assembly	1
trans-Golgi to periciliary membrane compartment transport	1
plasma membrane bounded cell projection assembly	1
ciliary transition zone assembly	1
protein transport within lipid bilayer	1
establishment of protein localization to plasma membrane	1
protein localization to plasma membrane	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
GTPase binding	1
binding	1
intracellular anatomical structure	1
centriole	1
cytoplasm	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
cilium	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

522 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RILPL2	RAB8A	P24407	928
RILPL2	RAB10	P61026	919
RILPL2	RAB36	O95755	731
RILPL2	RAB29	O14966	714
RILPL2	PPM1H	Q9ULR3	707
RILPL2	RAB12	Q6IQ22	668
RILPL2	RILP	Q96NA2	623
RILPL2	RAB35	Q15286	602
RILPL2	RHAG	Q02094	564
RILPL2	MYO5A	Q9Y4I1	521
RILPL2	EHBP1L1	Q8N3D4	501
RILPL2	RAB3A	P20336	484
RILPL2	RAB8B	Q92930	479
RILPL2	MITD1	Q8WV92	471
RILPL2	MAPK8IP3	Q9UPT6	452

IntAct

28 interactions, top by confidence:

A	B	Type	Score
RAB8A	RILPL2	psi-mi:“MI:0915”(physical association)	0.720
RILPL2	RAB8A	psi-mi:“MI:0914”(association)	0.720
RILPL2	RAB8A	psi-mi:“MI:0915”(physical association)	0.720
RILPL2	RAB8A	psi-mi:“MI:0407”(direct interaction)	0.720
	RAB8A	psi-mi:“MI:0407”(direct interaction)	0.680
RILPL2	RILPL2	psi-mi:“MI:0407”(direct interaction)	0.660
RILPL2	RILPL2	psi-mi:“MI:0915”(physical association)	0.660
RAB8A	WDR91	psi-mi:“MI:0914”(association)	0.600
RILPL2	RAB10	psi-mi:“MI:0915”(physical association)	0.560
RILPL2		psi-mi:“MI:0915”(physical association)	0.490
	RILPL2	psi-mi:“MI:0915”(physical association)	0.490
RILPL2		psi-mi:“MI:0915”(physical association)	0.370
	RILPL2	psi-mi:“MI:0915”(physical association)	0.370
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
WHAMMP3	EXOC5	psi-mi:“MI:0914”(association)	0.350
FRAT2	GSK3A	psi-mi:“MI:0914”(association)	0.350
WHAMMP3	CCDC22	psi-mi:“MI:0914”(association)	0.350
N	RILPL2	psi-mi:“MI:2364”(proximity)	0.270
	RILPL2	psi-mi:“MI:0915”(physical association)	0.000
sgrR	RILPL2	psi-mi:“MI:0915”(physical association)	0.000
TUBB4A	RILPL2	psi-mi:“MI:0915”(physical association)	0.000
HEXD	RILPL2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (11): RILPL2 (Affinity Capture-RNA), RILPL2 (Two-hybrid), RILPL2 (Affinity Capture-Western), RILPL2 (Synthetic Growth Defect), RILPL2 (Two-hybrid), RILPL2 (Two-hybrid), RILPL2 (Proximity Label-MS), RILPL2 (Affinity Capture-MS), RILPL2 (Affinity Capture-MS), RILPL2 (Affinity Capture-MS), RILPL2 (Affinity Capture-MS)

ESM2 similar proteins: A0PJP4, A0PJT0, A2VDP1, A4IFK7, D3ZUQ0, E9PSL7, O14578, O75665, P0C219, P49025, P97817, Q01850, Q0IHE5, Q14BN4, Q17QG3, Q28623, Q3LGD4, Q3SYW5, Q3URD3, Q3V079, Q4R3X1, Q4R7Y8, Q58A65, Q5DTM8, Q5EBL4, Q5R5R4, Q5VTR2, Q5ZJA3, Q5ZLS3, Q62172, Q62796, Q68CZ1, Q6AYA0, Q6DFC2, Q6DH86, Q6NRH3, Q6ZUS6, Q7Z3E2, Q86VS8, Q8BR07

Diamond homologs: A0PJP4, A0PJT0, A4IFK7, A4IGC3, D3ZUQ0, O76878, Q0IHE5, Q0P4J3, Q17QG3, Q5EBL4, Q6AYA0, Q6IP02, Q969X0, Q99LE1, Q9JJC6, Q5ND29

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

661 predictions. Top by Δscore:

Variant	Effect	Δscore
12:123423039:CTTA:C	donor_loss	1.0000
12:123423041:TA:T	donor_loss	1.0000
12:123423042:A:AC	donor_gain	1.0000
12:123423042:A:C	donor_loss	1.0000
12:123423042:ACAG:A	donor_gain	1.0000
12:123423043:C:CG	donor_gain	1.0000
12:123423043:CA:C	donor_gain	1.0000
12:123423043:CAG:C	donor_gain	1.0000
12:123423043:CAGC:C	donor_gain	1.0000
12:123423043:CAGCT:C	donor_gain	1.0000
12:123423153:GGCCA:G	acceptor_gain	1.0000
12:123423154:GCCA:G	acceptor_gain	1.0000
12:123423155:CCA:C	acceptor_gain	1.0000
12:123423155:CCAC:C	acceptor_gain	1.0000
12:123423156:CA:C	acceptor_gain	1.0000
12:123423156:CAC:C	acceptor_gain	1.0000
12:123423157:AC:A	acceptor_loss	1.0000
12:123423158:C:CC	acceptor_gain	1.0000
12:123423166:C:CT	acceptor_gain	1.0000
12:123423167:G:T	acceptor_gain	1.0000
12:123430509:T:TA	donor_gain	1.0000
12:123430529:T:TA	donor_gain	1.0000
12:123430536:C:CT	donor_gain	1.0000
12:123436080:ACCT:A	donor_gain	1.0000
12:123436080:ACCTC:A	donor_gain	1.0000
12:123436081:CCT:C	donor_gain	1.0000
12:123436081:CCTC:C	donor_gain	1.0000
12:123436081:CCTCC:C	donor_gain	1.0000
12:123436125:T:TA	donor_gain	1.0000
12:123423037:CACT:C	donor_loss	0.9900

AlphaMissense

1368 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:123430600:G:C	F133L	0.999
12:123430600:G:T	F133L	0.999
12:123430602:A:G	F133L	0.999
12:123430601:A:G	F133S	0.998
12:123430565:C:G	R145P	0.997
12:123430586:A:G	L138P	0.996
12:123430556:A:G	L148P	0.994
12:123430601:A:C	F133C	0.993
12:123430566:G:T	R145S	0.990
12:123430574:A:G	L142P	0.989
12:123436223:G:C	F66L	0.989
12:123436223:G:T	F66L	0.989
12:123436225:A:G	F66L	0.989
12:123430544:A:G	L152P	0.987
12:123430602:A:T	F133I	0.987
12:123436266:A:G	L52P	0.986
12:123430602:A:C	F133V	0.985
12:123436275:C:T	G49D	0.985
12:123430552:C:A	K149N	0.984
12:123430552:C:G	K149N	0.984
12:123436197:A:G	L75P	0.984
12:123436215:A:T	V69D	0.984
12:123436276:C:G	G49R	0.984
12:123436230:A:G	L64P	0.983
12:123436287:G:A	S45F	0.982
12:123430523:A:G	L159P	0.980
12:123436206:A:G	L72P	0.979
12:123436299:A:T	V41E	0.978
12:123436314:A:G	L36P	0.976
12:123436209:A:T	V71D	0.975

dbSNP variants (sampled 300 via entrez): RS1000040163 (12:123413593 G>A), RS1000058549 (12:123435052 C>G,T), RS1000114010 (12:123419160 A>G), RS1000122889 (12:123425863 A>G), RS1000186067 (12:123420625 C>A,T), RS1000240873 (12:123425540 G>A), RS1000306582 (12:123431118 A>G), RS1000335617 (12:123431438 G>A), RS1000460951 (12:123424813 G>A), RS1000508748 (12:123414394 G>A), RS1000550861 (12:123419318 C>T), RS1000642430 (12:123430340 C>A,T), RS1000673547 (12:123430377 C>T), RS1000725896 (12:123438034 G>A), RS1000744524 (12:123435260 C>T)

Disease associations

OMIM: gene MIM:614093 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

25 associations (top):

Study	Trait	p-value
GCST002149_20	Schizophrenia	2.000000e-08
GCST002539_19	Schizophrenia	2.000000e-14
GCST002598_15	Educational attainment	7.000000e-08
GCST004521_72	Autism spectrum disorder or schizophrenia	8.000000e-12
GCST004627_145	Lymphocyte count	6.000000e-13
GCST005956_10	Waist-to-hip ratio adjusted for BMI	6.000000e-08
GCST005958_11	Waist-to-hip ratio adjusted for BMI (age >50)	4.000000e-07
GCST005962_22	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	1.000000e-08
GCST006005_21	High density lipoprotein cholesterol levels	2.000000e-09
GCST006803_10	Schizophrenia	6.000000e-16
GCST007277_17	Tourette syndrome	2.000000e-06
GCST008163_151	Height	5.000000e-08
GCST010703_43	Brain morphology (MOSTest)	1.000000e-08
GCST012227_570	Hip circumference adjusted for BMI	4.000000e-09
GCST90011898_12	Alanine aminotransferase levels	2.000000e-15
GCST90020024_447	A body shape index	1.000000e-15
GCST90020024_448	A body shape index	7.000000e-09
GCST90020025_412	Waist-to-hip ratio adjusted for BMI	4.000000e-09
GCST90020025_418	Waist-to-hip ratio adjusted for BMI	1.000000e-20
GCST90020025_419	Waist-to-hip ratio adjusted for BMI	1.000000e-13
GCST90020025_420	Waist-to-hip ratio adjusted for BMI	4.000000e-10
GCST90020027_1218	Waist-hip index	3.000000e-19
GCST90020027_1219	Waist-hip index	5.000000e-13
GCST90020027_1220	Waist-hip index	4.000000e-10
GCST90020029_370	Waist circumference adjusted for body mass index	3.000000e-13

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004784	self reported educational attainment
EFO:0004587	lymphocyte count
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004346	neuroimaging measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, increases expression, decreases expression, affects expression	4
Valproic Acid	increases expression, affects expression	4
Cyclosporine	decreases expression	3
Acetaminophen	decreases expression, affects response to substance	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sodium arsenite	decreases expression	1
perfluorooctanoic acid	affects cotreatment, increases expression	1
aflatoxin B2	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
entinostat	increases expression	1
K 7174	decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
ICG 001	decreases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Leflunomide	decreases expression	1
Norethindrone Acetate	increases expression, affects cotreatment	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects binding, decreases expression	1
Cosmetics	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Doxorubicin	increases expression	1
Flame Retardants	affects cotreatment, increases expression	1
Plasticizers	affects cotreatment, increases expression	1
Progesterone	affects cotreatment, decreases expression	1
Quercetin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.